These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 19319016)
21. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449 [TBL] [Abstract][Full Text] [Related]
22. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates. Paradiso P Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657 [TBL] [Abstract][Full Text] [Related]
23. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Dagan R Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366 [TBL] [Abstract][Full Text] [Related]
25. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Rose M; Zielen S Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758 [TBL] [Abstract][Full Text] [Related]
26. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction. Center KJ; Strauss A Vaccine; 2009 May; 27(25-26):3281-4. PubMed ID: 19200818 [TBL] [Abstract][Full Text] [Related]
27. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165 [TBL] [Abstract][Full Text] [Related]
28. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Reinert RR; Paradiso P; Fritzell B Expert Rev Vaccines; 2010 Mar; 9(3):229-36. PubMed ID: 20218848 [No Abstract] [Full Text] [Related]
29. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Prymula R; Chlibek R; Splino M; Kaliskova E; Kohl I; Lommel P; Schuerman L Vaccine; 2008 Aug; 26(35):4563-70. PubMed ID: 18602724 [TBL] [Abstract][Full Text] [Related]
32. [Impact of 7-valent pneumococcal conjugate vaccination in a population with low to intermediate vaccination levels]. Salleras L; Domínguez A; Ciruela P; Izquierdo C; Borràs E; Enferm Infecc Microbiol Clin; 2009 May; 27(5):275-7. PubMed ID: 19386393 [TBL] [Abstract][Full Text] [Related]
33. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Dinleyici EC; Yargic ZA Expert Rev Vaccines; 2008 Nov; 7(9):1367-94. PubMed ID: 18980540 [TBL] [Abstract][Full Text] [Related]
34. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944 [TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Kumar D; Chen MH; Welsh B; Siegal D; Cobos I; Messner HA; Lipton J; Humar A Clin Infect Dis; 2007 Dec; 45(12):1576-82. PubMed ID: 18190318 [TBL] [Abstract][Full Text] [Related]
37. Understanding the link between pneumococcal serotypes and invasive disease. Soley C; Arguedas A Vaccine; 2009 Aug; 27 Suppl 3():C19-21. PubMed ID: 19535183 [TBL] [Abstract][Full Text] [Related]
38. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190 [TBL] [Abstract][Full Text] [Related]
39. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk]. van der Harst S Ned Tijdschr Geneeskd; 2007 Aug; 151(33):1853-4; author reply 1854. PubMed ID: 17874645 [No Abstract] [Full Text] [Related]
40. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]